Mathew R, Di Santo P, Jung RG, et al. - Milrinone did not differ significantly from dobutamine in terms of its therapeutic impacts in cardiogenic shock cases.

• A total of 192 patients with cardiogenic shock were treated; 96 received milrinone and another 96 received dobutamine.

• Primary outcome included a composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or start of renal replacement therapy.

• The individual components of the primary composite outcome comprised secondary outcomes.

• No significant differences were found between treatment groups for primary outcome as well as for secondary outcomes.